Sanofi GCVRZ 深 沪
等待开盘 12-20 09:30:00 美东时间
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 0.882
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 --
- 历史最高 0.882
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.153
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi Reaches Agreement With Trump Administration To Reduce Medicine Costs
Sanofi today announced an agreement with President Donald J. Trump's Administration to help ensure American patients have access to more affordable medicines while also supporting the role of the US in biopharmaceutical
今天 03:24
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.
12-18 23:14
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Sanofi expands its partnership with Dren Bio in a deal featuring $100 million upfront and up to $1.7 billion tied to a next-generation autoimmune B-cell therapy.
12-16 02:10
Canopy Growth To Acquire MTL Cannabis
Canopy Growth Corp. (NASDAQ: CGC) to acquire MTL Cannabis Corp. (OTCQX: MTLNF) for approx. 125 million CAD in cash and stock.
12-16 00:28
Cencora Strikes $5 Billion OneOncology Deal, Pauses Stock Buyback
Cencora agrees to buy a majority stake in OneOncology for about $5 billion, pauses buybacks, and reiterates fiscal 2026 sales and EPS guidance.
12-15 22:09
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks
Sanofi said its Phase 3 PERSEUS trial of tolebrutinib missed the primary endpoint in PPMS, ending plans for regulatory filing.
12-15 20:52
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for hemophilia and aTTP patients.
12-12 02:11
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks
U.S. regulators are reexamining infant RSV antibody treatments as safety questions surface, prompting new FDA scrutiny of products from major drugmakers.
12-10 00:30
Guggenheim Downgrades Sanofi to Neutral
Guggenheim analyst Seamus Fernandez downgrades Sanofi (NASDAQ:SNY) from Buy to Neutral.
12-09 20:16
Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook
Kamada ends its Phase 3 inhaled AAT trial after a futility analysis but maintains 2025 guidance and forecasts double-digit growth in 2026.
12-09 00:05
